Sort
10,766 grants matching “checkpoint inhibitor”
Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer
$300,357Shipra Gandhi · Emory University · K08 · FY2025 · CA
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
$300,190Douglas G McNeel · University Of Wisconsin-Madison · P01 · FY2024 · CA
Targeted Small Molecular Mertansine Delivery for Triple Negative Breast Cancer Treatment
$300,000Kaimin Cai · Iria Pharma, Llc · R43 · FY2019 · CA
Novel peptide drug conjugates for the treatment of triple-negative breast cancers: Direct anti-tumor activity and immuno-oncology preclinical studies.
$300,000Najib Lamharzi · Oncotherapy Solutions, Llc · R43 · FY2018 · CA
Polyionic Papillomavirus-like Particles (VLP) for the Treatment of HPV+ oropharyngeal squamous cell carcinomas (OPCs)
$300,000Joshua Weiyuan Wang · Pathovax, Llc · R41 · FY2017 · CA
Validation and humanization of a PET imaging agent that targets PD-L1.
$300,000Monica Gostissa · Agenus, Inc. · R43 · FY2016 · CA
Nanoscale Metal-Organic Frameworks as X-ray Activatable Cancer Vaccines
$300,000Ze-Qi Xu · Coordination Pharmaceuticals, Llc · N43 · FY2022 · CA
Discovery of therapeutic antibodies targeting breast cancer metastasis using Enabled G-Protein-Coupled Receptors
$300,000Mauro Mileni · Abilita Bio, Inc. · R43 · FY2016 · CA
Discovery of TREX1 Antagonists for Cancer Immunotherapy
$300,000Robert G Lowery · Bellbrook Labs, Llc · R43 · FY2020 · CA
VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus
$300,000Valerian Nakaar · Carogen Corporation · R43 · FY2020 · AI
Single Cell CytoScreen: An Imaging Platform for Evaluating Drug Combination Efficacy and Resistance in Individual Cancer Patients
$300,000Thomas Jacob · Cytoimage Inc. · R43 · FY2019 · CA
Development of immuno-PET agents for the selective imaging of CD8 T cells
$300,000Monica Gostissa · Agenus, Inc. · R43 · FY2016 · CA
Robust Predictor of Breast Cancer Risk
$300,000Harry Ostrer · Morgan And Mendel Genomics, Inc. · R41 · FY2017 · CA
CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES
$299,999Ferguson Tammy · Luna Innovations, Inc. · N01 · FY2017 · AI
Development of GPER agonists as Cancer Therapeutics
$299,998Todd W Ridky · Linnaeus Therapeutics, Llc · R41 · FY2018 · CA
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
$299,998Eric J Brown · Atrin Pharmaceuticals · R41 · FY2016 · CA
Collaborative Research: Integrative Adaptation of Dendrimer-peptide Conjugates for Cancer Immunotherapy
$299,997Petr Kral · University Of Illinois At Chicago · · FY2022 · MPS
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
$299,997Dirk Pleimes · Biosputnik Llc · R41 · FY2023 · HL
Therapeutic peptide for hepatocellular carcinoma
$299,983Niranjan B Pandey · Asclepix Therapeutics, Inc. · R43 · FY2018 · CA
Development of a vault nanovaccine for pancreatic cancer immunotherapy
$299,979Gayle Boxx · Aukera, Inc. · R43 · FY2019 · CA
G2 Role For Cdk2 in Human Cells
$299,958Gregory H. Enders · Fox Chase Cancer Center · R01 · FY2007 · GM
Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta
$299,956Prem Seth · Multivir, Inc. · R41 · FY2018 · CA
ITK inhibitors as an immunotherapeutic approach to colorectal cancer
$299,949Paul Changelian · Confluence Life Sciences, Llc · R43 · FY2016 · CA
Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients
$299,946Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R43 · FY2018 · CA
D-peptide inhibitors of SIRPα anti-phagocytic signaling
$299,945Daniel A Wettstein · Navigen, Inc. · R43 · FY2017 · CA